Phase I Study of CDK4/6 Inhibitor Ribociclib (LEE011) Combined With Gemcitabine in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 May 2018
At a glance
- Drugs Gemcitabine (Primary) ; Ribociclib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 22 May 2018 Status changed from suspended to recruiting.
- 27 Apr 2018 Status changed from recruiting to suspended to allow evaluation of patients per protocol
- 22 Jan 2018 Status changed from active, no longer recruiting to recruiting.